Clinical trial
The Safety and Effectiveness of 935U83 in HIV-Infected Patients
NCT00002338 · Glaxo Wellcome, Industry · Completed
Key facts
| NCT number | NCT00002338 |
|---|---|
| Title | The Safety and Effectiveness of 935U83 in HIV-Infected Patients |
| Official title | A Phase I Trial to Evaluate the Safety, Tolerance, and Pharmacokinetics of 935U83 After Multiple Dosing in Patients With HIV Infection |
| Lead sponsor | Glaxo Wellcome, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Raluridine |
| Enrollment | 40 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: